Download PDF
Pneumologie 2005; 59(5): 337-348
DOI: 10.1055/s-2004-830287
Serie: „Pleuraerkrankungen” (6)
© Georg Thieme Verlag Stuttgart · New York

Therapeutische Optionen beim malignen Pleuramesotheliom

Therapeutic Options in Malignant Pleural MesotheliomaM.  Serke1 , R.  Loddenkemper1
  • 1HELIOS Klinikum Emil von Behring, Lungenklinik Heckeshorn, Zentrum für Pneumologie und Thoraxchirurgie
Further Information

Publication History

Publication Date:
18 May 2005 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Beim malignen Pleuramesotheliom stehen mit Operation, Chemo- und Strahlentherapie verschiedene Therapieoptionen zur Verfügung. Bei der Mehrzahl der Patienten stehen Symptomlinderung und Überlebensverlängerung als palliative Therapieziele im Vordergrund. Eine Heilung ist nur in Ausnahmefällen bei Frühfällen durch eine multimodale Therapie mit radikaler OP, Bestrahlung und Chemotherapie zu erreichen. In dieser Übersicht wird die Rolle der Chirurgie diskutiert mit den Verfahren der radikalen extrapleuralen Pleuropneumonektomie oder der palliativen, wenig invasiven Pleurektomie und Dekortikation. Die Rolle der palliativen Bestrahlung mit dem Problem des Verbringens der notwendigen Dosis an die Pleura in enger Nachbarschaft zu Lunge, Herz, Leber und Nieren wird diskutiert. Die Möglichkeiten der Chemotherapie mit „älteren” Mono- und Kombinationstherapien werden diskutiert. Auch die jüngste große multizentrische Studie, die die Rolle von Cisplatin/Pemetrexed als neuen Therapiestandard beim malignen Pleuramesotheliom begründet, wird dargestellt. Erwähnt werden weitere, experimentelle Verfahren, wie Hyperthermie, Immuntherapie und neue Ansätze der Hemmung von EGFR und VEGF durch „kleine Moleküle” oder Antikörper. Letztlich muss individuell anhand von Tumorausdehnung, Begleitmorbidität, Allgemeinzustand und Patientenwunsch entschieden werden. Für die Mehrzahl der Patienten kommen thorakoskopische Talkumpleurodese und Chemotherapie, evtl. auch die Pleurektomie und Dekortikation, im Verlauf auch mit Bestrahlung von Problemzonen infrage.

Abstract

Malignant pleural mesothelioma may be treated with surgery, radiotherapy and chemotherapy. In most patients, the treatment remains palliative with symptom relief and a moderate survival gain. Only a minority of patients with early stage mesothelioma may be cured by a multimodal approach including radical surgery, chemotherapy, and radiotherapy. We discuss the role of surgery with either radical extrapleural pleuropneumonectomy or less invasive palliative pleurectomy and decortication, and the role of radiotherapy, in which the main problem is how to deliver sufficient doses to the pleural surface, sparing radiosensitive structures such as the lung, heart, liver, and kidneys. Chemotherapeutic options are discussed with ‘older’ mono- and combination regimens and the new promising combination cisplatinum/pemetrexed, now the ‘standard regimen’ for malignant pleural mesothelioma. Experimental approaches such as hyperthermia, interferons or interleukins, and ‘small molecules’ or antibodies inhibiting the EGFR oder VEGF receptor are under clinical evaluation. For the majoritiy of our patients we recommend talcum pleurodesis either by medical thoracoscopy or VATS, followed by chemotherapy with platinum/pemetrexed. Radiotherapy may be applied in case of local tumour growth. The individual therapeutic decision will depend on tumour stage, concomitant diseases, performance status, and on the patient’s preference.

Literatur

  • 1 Bittner R C. Bildgebende Diagnostik bei Pleuraerkrankungen.  Pneumologie. 2004;  58 238-254
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Müller K M. Pleuramesotheliom: Pathologie und Pathogenese.  Pneumologie. 2004;  58 670-679
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Frank W. Diagnostisches Vorgehen beim Pleuraerguss.  Pneumologie. 2004;  58 777-790
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Peto J, Decarli A, La Vecchia C. et al . The European mesothelioma epidemic.  Br J Cancer. 1999;  79 666-672
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Astoul P. Pleural mesothelioma.  Curr Opin Pulmon Med. 1999;  5 259-268
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Curran D, Sahmoud T, Therasse P. et al . Prognostic factors in patients with pleural mesothelioma: the EORTC experience.  J Clin Oncol. 1998;  16 145-152
    PubMedGoogle Scholar
  • 7 Sugarbaker D J, Strauss G M, Lynch T J. et al . Node status has prognostic significance in the multimodality therapy of diffuse malignant mesothelioma.  J Clin Oncol. 1993;  11 1172-1178
    PubMedGoogle Scholar
  • 8 Neumann V, Rutten A, Scharmach M. et al . Factors influencing long-term survival in mesothelioma patients - results of the German mesothelioma register.  Int arch occup environ health. 2004;  77 191-199
    CrossrefPubMedGoogle Scholar
  • 9 Ceresoli G L, Locati L D, Ferreri A J. et al . Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma.  Lung Cancer. 2001;  34 279-287
    CrossrefPubMedGoogle Scholar
  • 10 Edwards J G, Abrams K R, Leverment J N. et al . Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems.  Thorax. 2000;  55 731-735
    CrossrefPubMedGoogle Scholar
  • 11 Bueno R, Appasani K, Mercer H. et al . The α folate receptor is highly activated in malignant pleural mesothelioma.  J Thorac Cardiovasc surg. 2001;  121 1857-1862
    PubMedGoogle Scholar
  • 12 Edwards J G, Faux S P, Plummer S M. et al . Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma.  Clin Cancer Res. 2002;  8 1857-1862
    PubMedGoogle Scholar
  • 13 Rusch V W. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.  Lung Cancer. 1996;  14 1-12
    CrossrefPubMedGoogle Scholar
  • 14 British Thoracic Society Standards of Care Committee . Statement on the diagnosis and management of mesothelioma.  Thorax. 2001;  56 250-65
    CrossrefPubMedGoogle Scholar
  • 15 American Thoracic Society . Management of malignant pleural effusions.  Am J Resp Crit Care Med. 2000;  162 1987-2001
    PubMedGoogle Scholar
  • 16 Antony B VB, Loddenkemper R, Astoul P. et al . ERS/ATS Statement: Management of malignant pleural effusions.  Eur Respir J. 2001;  18 402-419
    CrossrefPubMedGoogle Scholar
  • 17 Berghmans T, Paesmans M, Lalami Y. et al . Activity of chemotherapy and immunotherapy on malignant mesothelioma. A systematic review of the literature with meta-analysis.  Lung Cancer. 2002;  38 111-121
    CrossrefPubMedGoogle Scholar
  • 18 Tomek S, Emri S, Krejcy K. et al . Chemotherapy for malignant pleural mesothelioma: past results and recent developments.  Brit J Cancer. 2003;  88 167-174
    PubMedGoogle Scholar
  • 19 Tomek S, Manegold C. Chemotherapy for malignant pleural mesothelioma. Past results and recent developnments.  Lung Cancer. 2004;  45S 103-119
    PubMedGoogle Scholar
  • 20 Pistolesi M, Rusthoven J. Malignant Pleural mesothelioma: update, current management and newer therapeutic strategies.  Chest. 2004;  126 1318-1329
    CrossrefPubMedGoogle Scholar
  • 21 Eberhardt W. Aufbruch zu neuen Ufern - das Mesotheliom wird eine therapierbare Erkrankung.  Pneumologie. 2004;  58 208-209
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Treasure T, Sedrakyan A. Pleural mesothelioma: little evidence, still time to do trials.  Review, Lancet. 2004;  364 1183-1185
    PubMedGoogle Scholar
  • 23 Vogelzang N J, Rusthoven J J, Symanowski J. et al . Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.  J Clin Oncol. 2003;  21 2636-2644
    CrossrefPubMedGoogle Scholar
  • 24 Klaveren R J van, Aerts J G, Bruin H de. et al . Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma.  Lung Cancer. 2004;  43 63-69
    CrossrefPubMedGoogle Scholar
  • 25 Ruth S van, Baas P, Zoetmulder F AN. Surgical treatment of malignant pleural mesothelioma: a review.  Chest. 2003;  123 551-555
    CrossrefPubMedGoogle Scholar
  • 26 Lee T T, Everett L L, Shu H K. et al . Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant mesothelioma.  J Thorac Cardiovasc Surg. 2002;  124 1183-1189
    CrossrefPubMedGoogle Scholar
  • 27 National Cancer research network trials portfolio. http://www.ncrn.org.uk/portfolio
    Google Scholar
  • 28 Butchart E G, Ashcroft T, Barnsley W C. et al . Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.  Thorax. 1976;  31 (1) 15-24
    CrossrefPubMedGoogle Scholar
  • 29 Sugarbaker D J, Jaklitsch M T, Bueno R. et al . Prevention, early detection and management of complications after 328 consecutive extrapleural pneumonectomies.  J Thorac Cardiovasc Surg. 2004;  128 138-146
    CrossrefPubMedGoogle Scholar
  • 30 Takagi K, Tsuchiya R, Watanabe Y. Surgical approach to pleural diffuse mesothelioma in Japan.  Lung Cancer. 2001;  31 57-65
    CrossrefPubMedGoogle Scholar
  • 31 Baldini E H, Recht A, Strauss G M. et al . Patterns of failure after trimodality therapy for malignant pleural mesothelioma.  Ann Thorac Surg. 1997;  63 334-338
    CrossrefPubMedGoogle Scholar
  • 32 Weder W, Kestenholz P, Taverna C. et al . Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.  J Clin Oncol. 2004;  22 3451-3457
    CrossrefPubMedGoogle Scholar
  • 33 Flores R M, Krug L, Rosenzweig E. et al .Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemithoracic radiation are feasable and effective for locally advanced malignant pleural mesothelioma (MPM). Proc ASCO 2004: a 71 993
    Google Scholar
  • 34 Rusch V W. Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma.  Semin Thorac Cardiovasc Surg. 1997;  9 367-372
    PubMedGoogle Scholar
  • 35 Soysal O, Karaoglanoglu N, Demiracan S. et al . Pleurectomy/decortication for palliation in malignant mesothelioma: results of surgery.  Eur J Cardiothorac Surg. 1997;  11 210-213
    CrossrefPubMedGoogle Scholar
  • 36 Rusch V W, Rosenzweig K, Venkatraman E. et al . A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.  J Thorac Cardiovasc Surg. 2001;  122 788-795
    CrossrefPubMedGoogle Scholar
  • 37 Davies S R, Tan L, Ball D L. Radiotherapy in the treatment of malignant mesothelioma of the pleura with special reference to its use in palliation.  Austral Radiol. 1994;  38 212-214
    PubMedGoogle Scholar
  • 38 Bissett D, Macbeth F R, Cram I. The role of palliative radiotherapy in malignant mesothelioma.  Clin Oncol. 1991;  3 315-317
    CrossrefPubMedGoogle Scholar
  • 39 Ahamad A, Stevens C W, Smythe W R. et al . Intensity-modified radiation therapy: a novel approach to the management of malignant pleural mesothelioma.  Int J Radiat Oncol Biol Phys. 2003;  55 768-775
    CrossrefPubMedGoogle Scholar
  • 40 Boutin C, Rey F, Viallat J R. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma: a randomised trial of local radiotherapy.  Chest. 1995;  108 754-758
    CrossrefPubMedGoogle Scholar
  • 41 Grondin S C, Sugarbaker D J. Pleuropneumonectomy in the treatment of malignant pleural mesothelioma.  Chest. 1999;  116 450S-454S
    CrossrefPubMedGoogle Scholar
  • 42 Ong S T, Vogelzang N G. Chemotherapy in malignant pleural mesothelioma. A review.  J Clin Oncol. 1996;  14 1007-1017
    PubMedGoogle Scholar
  • 43 Ryan C W, Herndon J, Vogelzang N J. A review of chemotherapy trials for malignant mesothelioma.  Chest. 1998;  113 66S-73S
    PubMedGoogle Scholar
  • 44 Baas P. Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine.  Semin Oncol. 2002;  29 62-69
    PubMedGoogle Scholar
  • 45 Mikulski S M, Costanzi J J, Vogelzang N J. et al . Phase II trial of a single weekly intravenous dose of Ranpirnase in patients with unresectable malignant mesothelioma.  J Clin Oncol. 2001;  20 274-281
    PubMedGoogle Scholar
  • 46 Vogelzang N J, Goutsou M, Courson J M. et al . Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B.  Cancer Chemother Pharmacol. 1990;  27 239-242
    CrossrefPubMedGoogle Scholar
  • 47 Steele J PC, Shamash J, Evans M T. et al . Phase II study of Vinorelbine in patients with malignant pleural mesothelioma.  J Clin Oncol. 2000;  18 3912-3917
    PubMedGoogle Scholar
  • 48 Fennell D A, Steele J PC, Shamash J. et al . Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma.  Lung Cancer. 2005;  47 277-281
    CrossrefPubMedGoogle Scholar
  • 49 Talbot S M, Rankin C, Taub R. et al . High-Dose ifosfamide with mesna and G-CSF in patients with unresectable malignant mesothelioma. A SWOG study.  Cancer. 2003;  98 331-336
    CrossrefPubMedGoogle Scholar
  • 50 Otterson G A, Herndon II J E, Watson D. et al . Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39 807).  Lung Cancer. 2004;  44 251-259
    CrossrefPubMedGoogle Scholar
  • 51 Solheim O P, Saeter G, Finnanger A M. et al . High-dose methotrexate in the treatment of malignant mesothelioma of the pleura.  Br J Cancer. 1992;  65 956-960
    PubMedGoogle Scholar
  • 52 Kindler H K, Belani C P, Herndon II J E. et al . Edatrexate with or without Leukovorin rescue for malignant mesothelioma. Sequential trials by the CALGB.  Cancer. 1999;  86 1985-1991
    CrossrefPubMedGoogle Scholar
  • 53 Vogelzang N J, Weisssman L B, Herndon II J E. et al . Trimetrexate in malignant mesothelioma: a cancer and leukaemia group B phase II study.  J Clin Oncol. 1994;  12 1436-1442
    PubMedGoogle Scholar
  • 54 Meerbeck J P van, Bass P, Debruyne C. et al . A phase II study of gemcitabine in patients with malignant pleural mesothelioma; EORTC.  Cancer. 1999;  85 2577-2582
    CrossrefPubMedGoogle Scholar
  • 55 Bischoff H G, Manegold C, Knopp M. et al . Gemcitabine may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma.  Proc Ann Meet Am Soc Clin Oncol. 1998;  17 A 1784
    PubMedGoogle Scholar
  • 56 Kindler H L, Millard F, Herndon II J E. Gemcitabine for malignant mesothelioma: A phase II trial by the CALGB.  Lung Cancer. 2001;  31 311-317
    CrossrefPubMedGoogle Scholar
  • 57 Byrne M J, Davidson J A, Musk A W. et al . Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study.  J Clin Oncol. 1999;  17 25-30
    PubMedGoogle Scholar
  • 58 Nowak A K, Byrne M J, Williamson R. et al . A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.  Br J Cancer. 2002;  87 491-496
    CrossrefPubMedGoogle Scholar
  • 59 Haarst J MW van, Baas P, Manegold Ch. et al . Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma.  British Journal of Cancer. 2002;  86 342-345
    CrossrefPubMedGoogle Scholar
  • 60 Favaretto A G, Aversa S M, Paccagnella A. et al . Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma.  Cancer. 2003;  97 2791-2797
    CrossrefPubMedGoogle Scholar
  • 61 Schütte W, Lauerwald K, Schreiber J. et al .Phase-II-Studie zur Behandlung des malignen Pleuramesothelioms mit Gemcitabin und Oxaliplatin. ASCO 2002: abstr. 1332
    Google Scholar
  • 62 Fizazi K, Doubre H, Le Chevalier T. et al . Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.  J Clin Oncol. 2003;  21 349-354
    CrossrefPubMedGoogle Scholar
  • 63 Meerbeeck J P van, Manegold C, Gaafar R. et al . A randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma (MPM). An Intergroup study of the EORTC Lung Cancer Group and NCIC; Proc.  Am Soc Clin Oncol. 2004;  22 abst. 7021
    PubMedGoogle Scholar
  • 64 Scagliotti G V, Shin D M, Kindler H L. et al . Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.  J Clin Oncol. 2003;  8 (21) 1556-1561
    PubMedGoogle Scholar
  • 65 Middleton G W, Smith I E, O'Brian M ER. et al . Good symptom relief with palliative MVP (Mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma.  Ann Oncol. 1998;  9 269-273
    CrossrefPubMedGoogle Scholar
  • 66 Samson M K, Wasser L P, Borden E C. et al . Randomised Comparison of cyclophosphamide, imidazole carcoxamide and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a sarcoma intergroup study.  J Clin Oncol. 1987;  5 86-91
    PubMedGoogle Scholar
  • 67 Chahinian A P, Antman K, Goutsou M. et al . Randomised phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.  J Clin Oncol. 1993;  11 1559-1565
    PubMedGoogle Scholar
  • 68 White S C, Anderson H, Jayson G C. et al . Randomised phase II study of cisplatin/etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma.  Ann Oncol. 2000;  11 201-206
    CrossrefPubMedGoogle Scholar
  • 69 Vogelzang T, Taub R, Shin D. et al . Phase III randomized trial of Onconase vs. Doxorubicin in patients with unresectable malignant mesothelioma: analysis of survival.  Proc Annu Meet Am Soc Clin Oncol. 2000;  18 A 2274
    PubMedGoogle Scholar
  • 70 Muers M F, Rudd R M, O'Brien M ER. et al . BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54 469 112.  Thorax. 2004;  59 144-148
    CrossrefPubMedGoogle Scholar
  • 71 Markman M, Cleary S, Pfeifle C. et al . Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma.  Cancer. 1986;  58 18-21
    PubMedGoogle Scholar
  • 72 Robinson B WS, Robinson C, Lake R A. Localised spontaneous mesothelioma regression-possible immunological mechanism.  Lung Cancer. 2001;  32 197-201
    CrossrefPubMedGoogle Scholar
  • 73 Astoul P, Picat-Joossen D, Viallat J R. et al . Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a phase II study.  Cancer. 1999;  83 2099-2104
    PubMedGoogle Scholar
  • 74 Mulatero C W, Penson R T, Papamichael D. et al . A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma.  Lung Cancer. 2001;  31 67-72
    CrossrefPubMedGoogle Scholar
  • 75 Castageto B, Zai S, Mutti L. et al . Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion. Results of a phase II study on 31 consecutive patients.  Lung Cancer. 2001;  31 303-310
    CrossrefPubMedGoogle Scholar
  • 76 Ardizzoni A, Pennucci M C, Castagneto B. et al . Recombinant Interferon α-2b in the treatment of diffuse mal. pleural mesothelioma.  Am J Clin Oncol. 1994;  17 80-82
    PubMedGoogle Scholar
  • 77 Boutin C, Nussbaum E, Monnet I. et al . Intrapleural treatment with recombinant γ-interferon in early stage malignant pleural mesothelioma.  Cancer. 1994;  74 2460-2467
    PubMedGoogle Scholar
  • 78 Astoul P, Viallat J R, Laurent J C. et al . Intrapleural recombinant IL-2 in passive Immunotherapy for malignant pleural effusion.  Chest. 1993;  103 2009-2013
    PubMedGoogle Scholar
  • 79 Monnet I, Breau J J, Moro D. et al . Intrapleural infusion of activated macrophages and γ-interferon in malignant pleural mesothelioma. A phase II study.  Chest. 2002;  121 (6) 1921-1927
    CrossrefPubMedGoogle Scholar
  • 80 Parra H S, Tixi L, Latteri F. et al . Combined regimen of cisplatin, doxorubicin and α-2b-interferon in the treatment of advanced malignant pleural mesothelioma.  Cancer. 2001;  92 650-656
    CrossrefPubMedGoogle Scholar
  • 81 Halme M, Knuuttila A, Vehmas T. et al . High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma.  Brit J Cancer. 1999;  80 1781-1785
    PubMedGoogle Scholar
  • 82 Mendes R, O'Brien M ER, Mitra A. et al . Clinical and immunological assessment of mycobacterium vaccae (SRLI72) with chemotherapy in patients with malignant mesothelioma.  Brit J Cancer. 2002;  86 336-341
    PubMedGoogle Scholar
  • 83 Sugarbaker D J, Flores R M, Jaklitsch M T. et al . Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma. Results in 183 patients.  J Thorac Cardiovasc Surg. 1999;  117 54-65
    CrossrefPubMedGoogle Scholar
  • 84 Hilaris B S, Nori D, Kwong E. et al . Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant mesothelioma.  Int J Radiat Oncol Biol Phys. 1984;  10 325-331
    PubMedGoogle Scholar
  • 85 Pass H I, Temek B K, Kranda K. et al . Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemo-therapy for malignant mesothelioma.  Ann Surg Oncol. 1997;  4 628-633
    PubMedGoogle Scholar
  • 86 Friedberg J S, Mick R, Stevenson J. et al . A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma.  Ann Thorac Surg. 2003;  75 952-959
    CrossrefPubMedGoogle Scholar
  • 87 Rusch V W, Saltz L, Venkatraman E. et al . A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.  J Clin Oncol. 1994;  12 1156-1163
    PubMedGoogle Scholar
  • 88 Mattson K, Holsti L R, Tammilehto L. et al . Multimodality treatment programs for malignant pleural Mesothelioma using high-dose hemithorax irradiation.  Int J Radiat Oncol Biol Phys. 1992;  24 643-650
    PubMedGoogle Scholar
  • 89 Serke M, Schönfeld N, Loddenkemper R. et al . Multimodal therapy in malignant pleural mesothelioma (MPM) including surgery and chemotherapy in 269 patients.  Eur Resp J. 2002;  20 (Suppl. 38) 187s
    PubMedGoogle Scholar
  • 90 Manzini V DP, Brollo A, Franceschi S. et al . Prognostic factors of malignant mesothelioma of the pleura.  Cancer. 1993;  72 410-417
    PubMedGoogle Scholar
  • 91 Bakhshandeh A, Bruns I, Traynor A. et al . Ifosfamide, carboplatin and etoposide combined with 41.8 whole body hyperthermia for malignant pleural mesothelioma.  Lung Cancer. 2003;  39 339-345
    CrossrefPubMedGoogle Scholar
  • 92 Bruns I, Kohlmann Th, Wiedemann G J. et al . Bewertung des therapeutischen Gewinns von Patienten mit Pleuramesotheliom unter Therapie mit 41,8 Ganzkörperhyperthermie plus Ifosfamid, Carboplatin und Etoposid (ICE) anhand des modifizierten Brunner-Score (MBS).  Pneumologie. 2004;  58 210-216
    Article in Thieme ConnectPubMedGoogle Scholar
  • 93 Albelda S M. Gene therapy for lung cancer and mesothelioma.  Chest. 1997;  111 144-149S
    PubMedGoogle Scholar
  • 94 Albelda S M, Wiewrodt R, Sterman D H. Gene therapy for lung neoplasms.  Clin Chest Med. 2002;  23 265-277
    CrossrefPubMedGoogle Scholar
  • 95 Smythe W R, Mohuiddin I, Ozveran M. et al . Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product.  J Thor Cardiov Surg. 2002;  123 (6) 119-198
    PubMedGoogle Scholar
  • 96 Villano J L, Husain A N, Stadler W M. et al . A phase II trial of imatinib mesylate in patients (pts) with malignant mesothelioma (MM) Proc.  Ann Meet Am Soc Clin Oncol. 2004;  22 abstr. 7200
    PubMedGoogle Scholar
  • 97 Garland L, Rankin C, Scott K. et al . Molecular correlates of the EGFR signaling pathway in association with SWOG S0218: A phase II study of oral EGFR tyrosine kinase inhibitor OSI-774 (NSC-718 781) in patients with malignant pleural mesothelioma (MPM) Proc.  Ann Meet Am Soc Clin Oncol. 2004;  22 abstr. 3007
    PubMedGoogle Scholar
  • 98 Vogelzang N J. Emerging insights into the biology and therapy of malignant mesothelioma.  Semin Oncol. 2002;  6 (suppl. 18) 35-42
    PubMedGoogle Scholar
  • 99 Kindler H L, Vogelzang N J, Chien K. et al . SU5416 in malignant mesothelioma: a Universitiy of Chicago Phase II Consortium Study.  Proc Ann Meet Am Soc Clin Oncol. 2001;  19 abstr. 1359
    PubMedGoogle Scholar
  • 100 Loddenkemper R. Management der malignen Pleuraergüsse.  Pneumologie. 2005;  59 120-135
    Article in Thieme ConnectPubMedGoogle Scholar
  • 101 Kennedy L, Sahn S A. Talc pleurodesis for the treatment of pneumothorax and pleural effusion.  Chest. 1994;  106 1215-1222
    CrossrefPubMedGoogle Scholar
  • 102 Nasreen N, Mohammed K A, Dowling P A. et al . Talc induces apoptosis in human malignant mesothelioma cells in vitro.  Am J Resp Crit Care Med. 2000;  161 595-600
    PubMedGoogle Scholar
  • 103 Waller D A, Morritta G N, Forty J. Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion.  Chest. 1995;  107 1454-1456
    PubMedGoogle Scholar

Bereits publizierte Beiträge zu dieser Serie:

Monika Serke

HELIOS Klinikum Emil von Behring · Lungenklinik Heckeshorn · Zentrum für Pneumologie und Thoraxchirurgie

Zum Heckeshorn 33

14109 Berlin

Email: mserke@berlin-behring.helios-kliniken.de

      >